Bafilomycin A1 from Streptomyces griseus
SIGMA/B1793 - ≥90% (HPLC)
CAS Number: 88899-55-2
Empirical Formula (Hill Notation): C35H58O9
Molecular Weight: 622.83
MDL Number: MFCD06795130
Linear Formula: C35H58O9
Product Type: Chemical
| antibiotic activity spectrum | fungi |
| assay | ≥90% (HPLC) |
| form | film |
| InChI | 1S/C35H58O9/c1-19(2)32-24 |
| InChI key | XDHNQDDQEHDUTM-JQWOJBOSSA |
| mode of action | DNA synthesis | interferes |
| enzyme | inhibits | |
| Quality Level | 300 ![]() |
| SMILES string | CO[C@H]1C=CC=C(C)C[C@H |
| storage temp. | −20°C |
| Application: | Bafilomycin A1 has been used: • as an autophagy inhibitor to study its effects on hepatic steatosis in human hepatocytes • as a vacuolar-type H+ -ATPase inhibitor to study its effects on the cell viability, percentage of PI-positive cells, and glucose-stimulated insulin secretion (GSIS) in mice INS-1 cells • as a vacuolar-type H+ -ATPase inhibitor to study its effects on tau degradation in human SH-SY5Y cells |
| Biochem/physiol Actions: | A specific inhibitor of vacuolar type H+-ATPase (V-ATPase) in animal cells, plant cells and microorganisms. |
| Biochem/physiol Actions: | Bafilomycin A1 inhibits autophagosome-lysosome fusion and autolysosome acidification, the steps involved in the autophagic process that is required for maintaining functional autophagic flux and cellular homeostasis. |
| Biochem/physiol Actions: | Specific inhibitor of vacuolar type H+-ATPase (V-ATPase). |
| General description: | Chemical structure: macrolide |
| Other Notes: | 2024 CiteAb Award Winner for Supplier Succeeding in Parkinson′s Research ![]() |
| Packaging: | 2, 10 μg in serum bottle |
| Hazard Codes | Xi |
| Risk Statements | 36/37/38 |
| Safety Statements | 26-36 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Purity | ≥90% (HPLC) |
| Storage Temp. | −20°C |
| UNSPSC | 12352200 |

